FDA Panel to Revisit Compounded Peptide Access in July 2025

The U.S. Food and Drug Administration announced on Wednesday that it will convene an outside advisory panel on July 23–24, 2025, to deliberate on whether certain peptides should be re-added to the list of substances compounding pharmacies are permitted to manufacture. A second meeting, addressing five additional peptides, is planned before February 2027 but has not yet been formally scheduled.

In 2023, the FDA removed 19 peptides from its bulk drug substances list — the roster of compounds compounding pharmacies can legally produce — citing insufficient evidence of safety and clinical utility. This decision significantly restricted access to peptides that had become staples in longevity, sports performance, and biohacking communities. The July panel will specifically discuss reinstating seven of those removed peptides.

Despite the limited peer-reviewed clinical data supporting many of these compounds, their popularity has surged, driven in part by social media influencers, podcasters, and high-profile advocates. BPC-157, TB-500, Epithalon, and similar peptides are frequently discussed for their purported benefits in tissue repair, inflammation reduction, hormonal regulation, and even lifespan extension — though robust human trial data remains sparse.

The regulatory reconsideration appears to be partly politically influenced. HHS Secretary Robert F. Kennedy Jr. publicly advocated for expanded peptide access during a February 2025 appearance on Joe Rogan's podcast, signaling a shift in the current administration's posture toward less conventional health interventions. This advocacy appears to have accelerated the FDA's timeline for revisiting the issue.

For the longevity community, the stakes are high. Many individuals currently source these peptides through gray-market channels or international pharmacies, raising legitimate concerns about purity, dosing accuracy, and contamination. Re-approval for compounding would enable access through licensed U.S. pharmacies with quality controls, potentially improving safety for users.

The advisory panel's recommendations are not binding, but the FDA typically gives them significant weight. Researchers, clinicians, and advocates in the longevity space will be watching closely, as the outcome could reshape the legal and clinical landscape for peptide therapeutics in the United States.